Is Propanc Biopharma going out of business?

PROPANC BIOPHARMA, INC. (PPCB) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

PROPANC BIOPHARMA, INC. (PPCB) scores 20 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 1024.65% (YoY)

Five questions, kept separate

Survival - Critical

Runway cannot be estimated from the available cash and cash-flow fields. Adjusted shares outstanding increased 1024.7% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

-34.2% net-cash backing support an extreme expectations pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 1024.65% (YoY)
• Debt / Equity: No financial debt (debt-free)
• Return on Assets: -411.08%
• Price / Earnings: Unprofitable (see Valuation)
• Effective Tax Rate: 0.00% (loss-making)
• Debt Maturity Runway: 50% long-term

Read from filings through 2026-05-14.

Price as of 2026-09-07.